Willow Biosciences Inc Stock Price, News & Analysis

Willow Biosciences has completed the sale of its operating subsidiary, Epimeron USA, to Mycofeast's U.S. subsidiary for US$2.76 million in cash. The transaction includes an escrow amount of US$275,975 held until September 17, 2025, subject to potential adjustments and indemnity claims.

Following the sale, significant management changes have occurred: CEO Dr. Chris Savile and SVP of Research and Development Dr. Trish Choudhary have resigned to join the purchaser. CFO Travis Doupe has been appointed as Interim CEO.

The company plans to use part of the proceeds for debt reduction while retaining the remainder pending a review of future cash requirements and potential opportunities. The transaction was executed through a share purchase agreement dated March 14, 2025, with detailed information available in the company's management information circular on SEDAR+.

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) held its annual general and special meeting on April 25, 2025, with 40.88% shareholder participation representing 59,214,893 common shares. Key approvals included:

• Election of 5 directors with strong majority support (84.5-88.4% approval): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, and Al Foreman
• Appointment of KPMG LLP as auditor (87.6% approval)
• Sale of Epimeron USA subsidiary (88.4% approval)
• Authorization for potential company name change to '2482118 Alberta ' (82.5% approval)

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has announced its financial results for 2024 and provided an update on the sale of its operating subsidiary. The company currently faces a working capital deficit of approximately CDN$180,000 excluding lease liabilities.

The company has entered into an agreement to sell its wholly-owned operating subsidiary, Epimeron USA, to a private UK-based entity for US$3.38 million in cash. Of this amount, US$900,000 will be held in escrow subject to adjustments. After anticipated adjustments, transaction costs, severance payments, and debt repayment, Willow expects to retain approximately CDN$1.1 million in cash.

Following the transaction, Willow will likely not meet TSX listing requirements and will undergo an expedited review process. The company will terminate key executives, including CEO Dr. Chris Savile and SVP of Research Dr. Trish Choudhary, as it will cease active operations.

Willow Biosciences (TSX: WLLW, OTCQB: CANSF), a biotechnology company focused on sustainable ingredient manufacturing, has announced the initiation of a formal strategic review process. The decision comes after unsuccessful attempts to secure financing under favorable shareholder terms amid challenging capital market conditions.

The strategic alternatives under consideration include:

• Sale of all or part of Willow's business and assets
• Complete company sale
• Merger with a third party
• Joint ventures
• Royalty or licensing arrangements
• Introduction of new strategic shareholders
• Various financing alternatives

The company has established a virtual data room for interested parties to review information upon signing a confidentiality agreement. While no definitive timeline has been set, management believes this process will benefit shareholders. The company does not plan to provide regular updates unless necessary or until a definitive transaction is approved.

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) reported record Q3 2024 revenue of $1.7 million, up from $674,000 in Q3 2023. The company signed a commercial license and royalty agreement with Kalsec, expecting milestone and tiered royalty payments. Willow also partnered with an Ag-Biotech company for a biopesticide strain, projected to generate $2 million in revenue. Additionally, Willow completed its first program with a leading API manufacturer and signed a second program to develop a large volume ingredient. The company raised $1.6 million through a private placement and increased its 2024 revenue guidance to over $4.5 million. Despite these advancements, Willow reported a net loss of $1.2 million for Q3 2024, an improvement from a $2.2 million loss in Q3 2023. The company expects further growth with 1-2 new partnerships by year-end 2024.

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has partnered with a global ingredient manufacturer to develop, scale, and commercialize a high-value ingredient from its internal portfolio. The collaboration includes R&D payments of up to $1.3 million and a 15-year tiered profit share arrangement. The 12-month research program targets a $1 billion global market segment currently dominated by chemically synthesized products. Willow aims to develop a high-purity, sustainable, bio-identical natural ingredient expected to be more cost-effective than chemical alternatives. The partner will handle regulatory compliance, manufacturing, and marketing responsibilities.

Willow Biosciences (TSX: WLLW; OTCQB: CANSF) has announced a second collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer. This new program aims to develop an optimized enzyme for large-scale manufacturing of a high-volume API used in a therapeutic with a global market exceeding $1 billion. The development phase is expected to last about six months, with potential milestone payments achievable by 2025. This marks Willow's 4th commercial agreement this year with potential milestone payments as early as next year. The collaboration builds on the success of their first program announced in January 2024, where Willow has already met certain development goals.

Willow Biosciences Inc. (TSX: WLLW; OTCQB: CANSF) has signed a commercial license and royalty agreement with Kalsec, Inc., a leading global producer of natural ingredients for the food and beverage industry. The agreement covers the use of Willow's technology for scaling and manufacturing a natural ingredient for savory food applications. Willow anticipates receiving milestone payments for the first pilot and industrial batches, followed by tiered royalty payments on net worldwide sales after launch.

The collaboration targets an existing $200M global market segment. Willow expects the research and development phase to be completed in 2024, with regulatory and scale-up work continuing into 2025. This agreement marks another successful transition of Willow's research program to commercial reality, highlighting the company's commitment to delivering safer and more sustainable natural products to consumers.

Willow Biosciences (TSX: WLLW; OTCQB: CANSF) reported record Q2 2024 revenue of $1.0 million, a 600% increase year-over-year. The company signed a strategic partnership with Laurus Labs to develop biobased processes for seven high-value APIs, expecting $4.0 million in guaranteed R&D payments in the first year. Willow anticipates over $4 million in revenue for 2024 from existing programs. The company also closed a private placement raising $1,639,737 and initiated a new feasibility study for bioactive pesticides production. With strengthened AI and business development capabilities, Willow continues to focus on revenue growth and cost reduction.